StockComparison Logo
vs

ADAP vs AARD

Comparison between Adaptimmune Therapeutics plc American Depositary Shares (ADAP, Company) and Aardvark Therapeutics Inc (AARD, Company).

Both ADAP and AARD are from the Healthcare sector.

ADAP vs AARD - Performance Comparison

Key Characteristics

Financial metrics and valuation ratios

Market Cap
ADAP
$87M
Winner
AARD
$87M
Max Drawdown
ADAP
99.81%
Winner
AARD
79.84%
Sharpe Ratio
Winner
ADAP
-0.21
AARD
-0.43
5Y Beta
ADAP
N/A
AARD
1.63
Industry
ADAP
Biotechnology
AARD
Biotechnology
P/E Ratio
ADAP
-0.50
Winner
AARD
-1.24
Debt to Equity
ADAP
423.98%
Winner
AARD
0.00%
Free Cash Flow Yield
ADAP
N/A
AARD
-70.94%
P/S Ratio
ADAP
1.39
AARD
N/A
P/B Ratio
Winner
ADAP
-1.23
AARD
1.03

ADAP vs AARD - Historical Returns

Returns include dividend reinvestment.

1M
ADAP
-62.65%
Winner
AARD
-32.72%
3M
ADAP
-45.10%
Winner
AARD
-35.89%
6M
ADAP
-80.19%
Winner
AARD
-72.86%
1Y
ADAP
-92.55%
Winner
AARD
-69.21%
5Y(CAGR)
ADAP
-59.08%
AARD
N/A
10Y(CAGR)
ADAP
-40.87%
AARD
N/A
Max(CAGR)
Winner
ADAP
-41.82%
AARD
-64.65%

ADAP vs AARD - Annual Returns (2015 - 2026)

Returns include dividend reinvestment.

YearADAPAARD
2026N/A-72.10%
2025-91.19%-8.28%
2024-27.79%N/A
2023-52.51%N/A
2022-64.04%N/A
2021-37.60%N/A
2020+341.80%N/A
2019-78.34%N/A
2018-19.01%N/A
2017+62.14%N/A
2016-65.74%N/A
2015-24.62%N/A

ADAP vs AARD Drawdown Comparison

The maximum drawdown for ADAP was -99.81%, occurring on Sep 5, 2025. This drawdown has not yet recovered.

The maximum drawdown for AARD was -79.84%, occurring on Mar 26, 2026. This drawdown has not yet recovered.

The current ADAP drawdown is -99.74%. The current AARD drawdown is -78.86%.

RankADAPAARD
#1-99.81%
Jun 16, 2015 - Sep 5, 2025
-79.84%
Oct 7, 2025 - Mar 26, 2026
#2-14.05%
May 7, 2015 - Jun 11, 2015
-59.42%
Feb 20, 2025 - Oct 7, 2025
#3N/A-7.06%
Feb 13, 2025 - Feb 19, 2025

Correlation

Correlation between ADAP and AARD is 0.31 which considered as a weak positive correlation - the stocks show a slight tendency to move together.

0.31
-101

Select Stocks to Compare